Drugs / SAR443809
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06326814 | Oct 2021 → May 2023 | paroxysmal nocturnal hemoglobinuria | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR443809 | “6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 1” NCT06326814 ↗ |
| Modality | Monoclonal antibody | “Humanized anti-Factor Bb monoclonal antibody” NCT06326814 ↗ |
| Route | Intravenous | “Route of administration:IV and SC routes of administration” NCT06326814 ↗ |
| Route | Subcutaneous | “Route of administration:IV and SC routes of administration” NCT06326814 ↗ |